Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UE 2343

Next Previous
Drug Profile

UE 2343

Alternative Names: UE2343; Xanamem

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Edinburgh
  • Developer Actinogen Medical
  • Class Antidementias; Small molecules
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 01 Oct 2019 Efficacy and safety data from a phase I XanaHES trial in Alzheimer's disease released by Actinogen Medical
  • 26 Jun 2019 Actinogen Medical initiates a phase I target occupancy PET study
  • 24 Apr 2019 Actinogen Medical plans clinical development program for Cognition disorders (in mood disorders and schizophrenia)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top